more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$2.61 USD

+0.02 (0.77%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

by Zacks Equity Research Published on February 26,2021

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod

by Zacks Equity Research Published on December 24,2020

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

biotechs

Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on December 04,2020

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALLOPositive Net Change

Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses

by Zacks Equity Research Published on November 04,2020

Allogene (ALLO) reports no revenues for the third quarter of 2020.

Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on September 04,2020

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALLOPositive Net Change

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

by Zacks Equity Research Published on August 06,2020

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on June 26,2020

Is (ALLO) Outperforming Other Medical Stocks This Year?

ALLOPositive Net Change

Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on June 10,2020

Is (ALLO) Outperforming Other Medical Stocks This Year?

ALLOPositive Net Change

Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?

by Zacks Equity Research Published on June 05,2020

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALLOPositive Net Change

Moving Average Crossover Alert: Allogene Therapeutics

by Zacks Equity Research Published on May 27,2020

Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ALLOPositive Net Change

medical

Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on May 22,2020

Is (ALLO) Outperforming Other Medical Stocks This Year?

ALLOPositive Net Change

Implied Volatility Surging for Allogene (ALLO) Stock Options

by Zacks Equity Research Published on May 19,2020

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

ALLOPositive Net Change

medical

Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher

by Zacks Equity Research Published on May 18,2020

Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

medical

Will Allogene Therapeutics Continue to Surge Higher?

by Zacks Equity Research Published on May 13,2020

As of late, it has definitely been a great time to be an investor Allogene Therapeutics

ALLOPositive Net Change

medical

How Allogene (ALLO) Stock Stands Out in a Strong Industry

by Zacks Equity Research Published on May 11,2020

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ALLOPositive Net Change

medical

Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

by Zacks Equity Research Published on May 07,2020

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More

by Kinjel Shah Published on May 05,2020

Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah Published on May 05,2020

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)

by Zacks Equity Research Published on May 05,2020

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

ALLOPositive Net Change

medical

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 04,2020

Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.